1513:HKEXChung-Hsin Electric and Machinery Manufacturing Corp. Analysis

Livzon Pharma is trading at HK$27.7, which sits below its 20‑day (HK$28.73), 50‑day (HK$29.24) and 200‑day (HK$32.16) simple moving averages, signaling a bearish technical backdrop. The stock is hovering just above the calculated support of HK$27.16 and faces resistance near HK$30.10, while the RSI of 38.8 points to a mildly oversold condition and the MACD remains in bearish territory. Volume is on the rise, yet the 30‑day volatility is elevated at roughly 25.5%, and beta is near zero, indicating limited correlation with broader market moves.
On the fundamentals side, Livzon trades at a forward PE of about 10×, far cheaper than the industry average of 26×, and offers a solid dividend yield of 4.33% with a payout ratio under 50%, suggesting dividend sustainability. The balance sheet is strong with cash far exceeding debt, and profitability metrics are robust (ROE ~16%, gross margin ~64%). However, the DCF‑derived fair value of HK$24.5 is below the current price, hinting at modest overvaluation, while analyst price targets around HK$38‑41 imply upside potential. Market sentiment is in “Greed” mode per the fear‑greed index, adding a bullish tilt despite the technical downside.